Such agents could be useful for the treatment or management of thrombotic complications and be employed as tools in studies designed to assess the degree to which NEFA-mediated alterations in plasma Zn2+ dynamics contribute to thrombotic disorders in high-risk groups. Here, NUCB2 is linked to thrombotic disease.